NCT02254122View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

February 28, 2005

Conditions
Healthy
Interventions
DRUG

BEA 2180 BR

DRUG

Placebo

DEVICE

Respimat®

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY